CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 670 enrolled
Drug / intervention
Palonosetron +3 moredrug
Likely dose
Palonosetron 1 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01395901
NCT01395901Phase 3Completed

A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients.

Helsinn Healthcare SA·interventional·Posted Jul 18, 2011·Updated Jul 30, 2014

In Brief

A Phase 3 clinical trial evaluating Palonosetron, Ondansetron, and 2 other interventions for Postoperative Nausea and Vomiting. Completed, enrolled 670 participants across 44 sites in 8 countries.

Detailed Summary

The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in children aged from neonates up to less than 17 years undergoing elective surgical procedures requiring general intravenous anesthesia. The secondary objective is to evaluate the safety and tolerability of IV palonosetron in pediatric patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Czechia, Hungary, Poland, Puerto Rico, Russia, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 18, 2011
Enrollment StartJun 1, 2011
Primary CompletionMar 1, 2012
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.0 years ago

Interventions

Palonosetrondrug

Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)

Ondansetrondrug

Single dose Ondansetron IV: * 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg; * 13 years to less than 17 years dose: 4 mg

Placebo to Ondansetrondrug

Placebo to Palonosetrondrug